• 2023 consolidated turnover of €4.6 million net of studies for ABIONYX
• Cash of €4.1 million as of December 31, 2023
Toulouse, FRANCE, Lakeland, UNITED STATES, February 29, 2024, 6:00 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), new generation biotechnology company dedicated to the discovery and development of innovative therapies based on apolipoprotein alone recombinant human apoA-I in the world, today provides an update on its activity and cash and cash equivalents as of December 31, 2023.